Path ID: DB09119_MESH_D004828_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C416835 | eslicarbazepine acetate | Drug |
| MESH:C571001 | eslicarbazepine | Drug |
| InterPro:IPR001696 | Voltage gated sodium channel, alpha subunit | GeneFamily |
| GO:0035725 | sodium ion transmembrane transport | BiologicalProcess |
| GO:0019228 | neuronal action potential | BiologicalProcess |
| HP:0011097 | Epileptic spasm | PhenotypicFeature |
| MESH:D004828 | Epilepsies, Partial | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Eslicarbazepine Acetate | HAS METABOLITE | Eslicarbazepine |
| Eslicarbazepine | DECREASES ACTIVITY OF | Voltage Gated Sodium Channel, Alpha Subunit |
| Voltage Gated Sodium Channel, Alpha Subunit | POSITIVELY REGULATES | Sodium Ion Transmembrane Transport |
| Sodium Ion Transmembrane Transport | REGULATES | Neuronal Action Potential |
| Neuronal Action Potential | CONTRIBUTES TO | Epileptic Spasm |
| Epileptic Spasm | POSITIVELY CORRELATED WITH | Epilepsies, Partial |
Comment: The antiseizure mechanism of action based on the voltage sodium channels is not a consensus (https://en.wikipedia.org/wiki/Eslicarbazepine_acetate#Mechanism_of_action). The drug could also bind to calcium channels (https://go.drugbank.com/drugs/DB09119#mechanism-of-action). Note that the protein target listed in DrugBank (https://go.drugbank.com/drugs/DB09119#BE0005793) does not seem to be involved in epilepsy, but rather in inflammation and pain.
Reference: